Compare Abbott Laboratories (ABT) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Paycom Software Inc — how do they compare? Abbott Laboratories trades at $95.8 (market cap $166.94B), while Paycom Software Inc trades at $138.3 (market cap $6.70B). The key difference: Abbott Laboratories is far larger — about 24.9× Paycom Software Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | PAYC | |
|---|---|---|
Market Cap | $166.94B | $6.70B |
Sector | Health | Technology |
52-Week High | $136.62 | $238.80 |
52-Week Low | $82.57 | $113.59 |
Enterprise Value | $193.69B | $7.31B |
Dividend Yield | 2.63% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Paycom Software (PAYC) trades at $143.78, up 3.28% on the day, with a bullish technical signal and strong fundamentals including a 22.44% net income margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $678.9 million in 2025. Analyst consensus is mixed with a $151 price target, while recent news highlights its value stock appeal and industry awards.
The outlook for PAYC is positive with solid revenue growth and profitability, though risks include competitive pressures and market volatility. The stock's current valuation metrics, such as a P/E of 16.19, suggest room for upside if earnings momentum continues, but investors should weigh execution risks against the bullish analyst sentiment and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
